Top Premarket Gainers

MT Newswires Live10-28

Evoke Pharma (EVOK) shares surged more than 130% pre-bell Monday after the company reported results from a real-world study showing significant statistical improvement for its diabetic gastroparesis nasal therapy over oral metoclopramide.

Monte Rosa Therapeutics (GLUE) shares advanced 42% after the company said it secured a global license deal with Novartis (NVS) to advance therapies for multiple immune-mediated conditions.

Revance Therapeutics (RVNC) shares rose 22%, rebounding from Friday's slide.

Focus Impact Acquisition (FIAC) shares were up 15%, adding to Friday's gains.

MEI Pharma (MEIP) shares increased 12% following a muted session.

Price: 11.75, Change: +6.62, Percent Change: +129.04

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2478101332?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-28 19:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2478101332","market":"us","top_or_hot":-1,"title":"Top Premarket Gainers","media":"MT Newswires Live","content":"<html><body><p> Evoke Pharma (EVOK) shares surged more than 130% pre-bell Monday after the company reported results from a real-world study showing significant statistical improvement for its diabetic gastroparesis nasal therapy over oral metoclopramide.</p><p><a href=\"https://laohu8.com/S/GLUE\">Monte Rosa Therapeutics</a> (GLUE) shares advanced 42% after the company said it secured a global license deal with Novartis (NVS) to advance therapies for multiple immune-mediated conditions.</p><p>Revance <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (RVNC) shares rose 22%, rebounding from Friday's slide.</p><p>Focus Impact Acquisition (FIAC) shares were up 15%, adding to Friday's gains.</p><p><a href=\"https://laohu8.com/S/MEIP\">MEI Pharma</a> (MEIP) shares increased 12% following a muted session.</p><p>Price: 11.75, Change: +6.62, Percent Change: +129.04</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Top Premarket Gainers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTop Premarket Gainers\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-28 19:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Evoke Pharma (EVOK) shares surged more than 130% pre-bell Monday after the company reported results from a real-world study showing significant statistical improvement for its diabetic gastroparesis ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BFTCPJ56.SGD","symbol_name":"Janus Henderson Global Life Sciences A Acc SGD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2478101332","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2478101332","pubTimestamp":1730116088,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Evoke Pharma (EVOK) shares surged more than 130% pre-bell Monday after the company reported results from a real-world study showing significant statistical improvement for its diabetic gastroparesis n","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BK4007":"制药","RVNC":"Revance Therapeutics Inc","BK4578":"CAR-T","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","MEIP":"MEI Pharma","BK4588":"碎股","BK4532":"文艺复兴科技持仓","BK4539":"次新股","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","NVS":"诺华","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","EVOK":"Evoke Pharma Inc.","BK4585":"ETF&股票定投概念","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4139":"生物科技","GLUE":"Monte Rosa Therapeutics"},"translate_title":"盘前涨幅最大的股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVS":1,"RVNC":0.9,"MEIP":0.9,"EVOK":0.9,"FIAC":0.9,"GLUE":0.9},"content_text":"Evoke Pharma (EVOK) shares surged more than 130% pre-bell Monday after the company reported results from a real-world study showing significant statistical improvement for its diabetic gastroparesis nasal therapy over oral metoclopramide.Monte Rosa Therapeutics (GLUE) shares advanced 42% after the company said it secured a global license deal with Novartis (NVS) to advance therapies for multiple immune-mediated conditions.Revance Therapeutics (RVNC) shares rose 22%, rebounding from Friday's slide.Focus Impact Acquisition (FIAC) shares were up 15%, adding to Friday's gains.MEI Pharma (MEIP) shares increased 12% following a muted session.Price: 11.75, Change: +6.62, Percent Change: +129.04","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2478101332"}